Low Dose Cyclophosphamide in Combination with Elotuzumab - a Novel Immunotherapeutic Strategy for Multiple Myeloma

被引：0
|
作者：
Feerick, Claire L. [1 ,2 ,3 ]
Lynch, Kevin [2 ,3 ,4 ]
Krawczyk, Janusz [2 ,5 ,6 ]
O'Dwyer, Michael [2 ,5 ,6 ]
Ryan, Aideen [1 ,2 ,3 ,4 ,6 ]
机构：
[1] NUI Galway, Sch Med, Coll Med,Nursing & Hlth Sci, Discipline Pharmacol & Therapeut, Galway, Ireland
[2] NUI Galway, Sch Med, Coll Med, Nursing & Hlth Sci, Galway, Ireland
[3] NUI Galway, Regenerat Med Inst REMEDI, Sch Med,Nursing & Hlth Sci, Coll Med, Galway, Ireland
[4] Galway Univ Hosp, Dept Hematol, Galway, Ireland
[5] Blood Canc Network Ireland, Galway, Ireland
[6] NUI Galway, SFI Res Ctr Med Devices, CURAM, Galway, Ireland
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152432
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Lonial, Sagar
    Vij, Ravi
    Harousseau, Jean-Luc
    Facon, Thierry
    Moreau, Philippe
    Mazumder, Amitabha
    Kaufman, Jonathan L.
    Leleu, Xavier
    Tsao, L. Claire
    Westland, Christopher
    Singhal, Anil K.
    Jagannath, Sundar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1953 - 1959
  • [2] Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma
    Eleutherakis-Papaiakovou, Evangelos
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (11) : 921 - 928
  • [3] Low dose thalidomide in combination with dexamethasone and cyclophosphamide for management of relapsed/refractory multiple myeloma.
    Caravita, T
    Siniscalchi, A
    Niscola, P
    Santinelli, S
    Buccisano, F
    Montanaro, M
    De Fabritiis, P
    Amadori, S
    BLOOD, 2003, 102 (11) : 382B - 383B
  • [4] Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study
    Lonial, S.
    Vij, R.
    Harousseau, J.
    Facon, T.
    Moreau, P.
    Leleu, X.
    Westland, C.
    Singhal, A. K.
    Jagannath, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE 1/2 STUDY
    Lonial, S.
    Vij, R.
    Harousseau, J. L.
    Facon, T.
    Moreau, P.
    Mazumder, A.
    Kaufman, J.
    Leleu, X.
    Tsao, C.
    Fry, J.
    Singhal, A.
    Jagganath, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 157 - 158
  • [6] A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    Moreau, Philippe
    Reece, Donna E.
    White, Darrell J.
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn
    Singhal, Anil K.
    Richardson, Paul G.
    BLOOD, 2011, 118 (21) : 141 - 142
  • [7] Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
    Daniel E. Meyers
    Satbir Thakur
    Chandini M. Thirukkumaran
    Don G. Morris
    Blood Cancer Journal, 7
  • [8] Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
    Meyers, Daniel E.
    Thakur, Satbir
    Thirukkumaran, Chandini M.
    Morris, Don G.
    BLOOD CANCER JOURNAL, 2017, 7
  • [9] Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results
    Lonial, Sagar
    Vij, Ravi
    Harousseau, Jean-Luc
    Facon, Thierry
    Kaufman, Jonathan
    Mazumder, Amitabha
    Moreau, Philippe
    Leleu, Xavier
    Fry, John
    Singhal, Anil
    Jagannath, Sundar
    BLOOD, 2009, 114 (22) : 179 - 180
  • [10] Addition of low dose Cyclophosphamide to the combination of Thalidomide and Dexamethasone in patients with relapsed/refractory multiple myeloma.
    Di Raimondo, F
    Pennisi, A
    Buglio, D
    Fiumara, P
    Palumbo, GA
    Giustolisi, R
    BLOOD, 2003, 102 (11) : 385B - 385B
12345